Preeclampsia and MicroRNAs by Devor, Eric J et al.
Proceedings in Obstetrics and Gynecology, 2013;3(1):2 
 
Please cite this paper as: Devor EJ, Santillan DA, Santillan MK.  Preeclampsia and MicroRNAs. Proc Obstet 
Gynecol. 2013;3(1):  Article 2 [ 10 p.]. Available from: http://ir.uiowa.edu/pog/.  Free full text article. 
Corresponding author: Mark Santillan, MD, Division of Maternal Fetal Medicine, Department of Obstetrics and 
Gynecology, University of Iowa Hospitals and Clinics, 31330 PFP, 200 Hawkins Drive, Iowa City, IA 52242, Phone: (319) 
356-3180, Email: mark-santillan@uiowa.edu  
This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported License 
(http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any 
medium, provided the original work is properly cited. 
1 
 
Preeclampsia and MicroRNAs 
Eric J. Devor, PhD,1 Donna A. Santillan, PhD,1 Mark K. Santillan, MD1 
  Keywords: pre-eclampsia, MicroRNAs, pregnancy, exosome 
Abstract 
Preeclampsia is a critical gestational condition 
that threatens the life of both mother and child. 
One of the most serious aspects of 
preeclampsia hampering both clinical 
management and scientific understanding is that 
there are, as yet, no early warning signs or risk 
markers. The discovery of microRNAs 
(miRNAs), tiny post-transcriptional regulators of 
gene expression, offers potentially fertile ground 
for developing such markers. The current state 
of knowledge about miRNAs in preeclampsia is 
presented along with information regarding 
miRNA detection in peripheral fluids that could 
lead to minimally invasive risk assessment. 
1The Department of Obstetrics and Gynecology, 
Roy J. and Lucille A. Carver College of 
Medicine, The University of Iowa, Iowa City, 
Iowa, USA. 
Introduction 
Hypertension complicates up to 10% of 
all pregnancies worldwide. In the United 
States, preeclampsia affects 5-7% of all 
pregnancies, approximately 300,000 
pregnancies a year, yet it 
disproportionately represents 15% of all 
maternal-fetal morbidity and mortality. 
Preeclampsia is known to cause 
immediate maternal-fetal morbidities 
such as growth restriction, 
oligohydramnios, fetal death, maternal 
seizures, stroke, cerebrovascular 
hemorrhage, and maternal death.1 
Mothers with a history of preeclampsia 
are at increased risk of future cardiac 
disease including myocardial infarction 
and stroke.2,3,4 Children born from 
preeclamptic pregnancies are also at 
increased risk of stroke,5 epilepsy,6 and 
metabolic, nutritional and blood disease7 
in later childhood or as an adult. Clearly, 
preeclampsia has immediate and long 
term effects on both the fetus and 
mother. However, its pathogenesis is 
poorly understood. 
The two-stage etiologic model has been 
the prevailing view of the pathogenesis 
of preeclampsia. The first stage is the 
existence of poor placentation exhibited 
by poor trophoblastic invasion, poor 
remodeling of spiral arteries, and 
increased placental necrosis. Despite 
the many mechanisms that may 
produce the preeclamptic phenotype, 
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data demonstrate that the placenta 
plays the central role in the development 
of preeclampsia. In preeclampsia, there 
is abnormal cytotrophoblast 
differentiation and apoptosis,8,9 
incomplete spiral artery invasion,9 and 
decreased blood flow to and from the 
placenta. Trophoblast necrosis releases 
cell fragments into the maternal 
bloodstream which trigger a systemic 
immunologic response and placental 
oxidative stress.10,11,12 As seen in Figure 
1, Redman and Sargent have recently 
updated this 2 stage model to include an 
important etiologic component: poor 
immunoregulation that involves a 
dysregulation of regulatory T cells, IDO, 
and dendritic cells.13  Multiple processes 
involving placental dysregulation, 
endothelial cell dysfunction, 
immunology, oxidative stress, altered 
vascular biology, and angiogenesis 
make finding a singular cause of 
preeclampsia nearly impossible.14 As 
preeclampsia is a disease resulting from 
multiple pathways, the development of a 
predictive model and the search for a 
therapeutic pathway for preeclampsia 
may need to come from the regulation of 
these multiple pathways.  
  
 
 
MicroRNAs and Human Disease 
MicroRNAs, as a group, represent a 
level of regulation that may address all 
these multiple pathways at once and 
differentially throughout pregnancy.  
MicroRNAs (miRNAs) are 21-23nt long 
regulatory RNAs first identified in 
Caenorhabtidis elegans in 1993.15,16 
Since their discovery, miRNAs have 
been found in nearly every eukaryotic 
species and have been shown to play 
critical roles in gene regulation in both 
normal and pathologic cellular 
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processes.17,18 The majority of primary 
miRNA transcripts (pri-miRNAs) are 
initiated by RNA polymerase II. These 
transcripts can be from a few hundred to 
several thousand nucleotides in length 
and are produced from both inter-genic 
regions and introns. Pri-miRNAs contain 
within them one or more shorter 
sequences that form a characteristic 
thermodynamically stable hairpin 
structure. These hairpins in the nucleus 
induce the formation of an RNA-protein 
complex composed of the hairpin and 
RNase III endonuclease DROSHA along 
with its protein partner DGCR8.19 The 
latter protein binds the pre-miRNA 
hairpin and DROSHA excises it from the 
pri-miRNA transcript. Nuclear 
processing of these miRNAs involves 
multiple enzymes and proteins including 
Exportin 5, which binds the hairpin and 
transports it out of the nucleus.20 In the 
cytoplasm, the pre-miRNA interacts the 
RNase III endonuclease DICER which 
binds to the hairpin along with its partner 
protein TRBP (TAR RNA binding 
protein). This RNA-protein complex 
allows DICER to cleave the hairpin in a 
precise manner to produce a 21-23nt 
double-stranded RNA composed of the 
mature miRNA effector sequence and 
its complement.21,22 Finally, this dsRNA 
is processed by an Argonaute protein, 
AGO2, which is a primary component of 
the ribonucleoprotein complex called 
RISC (RNA induced silencing complex). 
The mature miRNA strand is selected in 
RISC and transported to the target 
messenger RNA (mRNA) where it binds 
in an antisense orientation to a target 
sequence in the 3’ untranslated region 
of the message. Once bound, the 
miRNA:mRNA complex will either 
participate in mRNA degradation or 
translational repression of the 
message.17,23 MicroRNA regulation of 
gene expression is often highly specific 
in terms of tissue and/or developmental 
stage or pathology. 
Although the mechanisms of these 
regulatory processes are not fully 
delineated, their functional importance is 
evidenced by the fact that miRNAs have 
been found in nearly every eukaryotic 
species. As of Release 18 (November, 
2011) of the miRNA repository 
miRBase, there are nearly 2,000 miRNA 
loci in the human genome. The vast 
majority of these has been discovered in 
just the past few years by deep 
sequencing of specialized tissue targets 
and are only expressed as a few copies 
in one tissue type or pathology. The one 
human disease in which extensive 
miRNA expression studies have been 
carried out is cancer.24,25 More than two-
thirds of the current miRNA literature is 
composed of miRNA studies of cancers. 
In the field of obstetrics and gynecology, 
the vast majority of the miRNA literature 
is addressed to cancers and, in 
particular, ovarian cancers. However, 
there have been a number of miRNA 
expression studies of uterine cancers of 
which two of the most extensive have 
been carried out by us.26,27 With regard 
to other OB/GYN pathologic processes, 
the literature is less extensive. Among 
these, preeclampsia has received the 
most attention, but even this literature is 
small. 
MicroRNAs and the Development of 
Preeclampsia 
To date, there have been four surveys 
of miRNA expression in preeclampsia 
(Table 1). Taking these four surveys 
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together, a total of 67 different human 
miRNAs have been shown to be 
significantly dysregulated in 
preeclampsia as compared with 
controls. Among these, only three 
miRNAs (miR-181a, miR-195, and miR-
584) are reported in two of the four 
studies and only one, miR-210, is found 
in three of the four studies. Replication 
of increased miR-210 expression in 
preeclampsia is important as it is known 
to be the most hypoxia-inducible 
microRNA.28 In addition, there are 
contradictory data concerning 
expression of some miRNAs.  For 
example, Hu et al concluded that miR-
195 is upregulated in placentas from 
severe preeclamptic pregnancies.29  In 
contrast, Zhu et al demonstrate that 
miR-195 is downregulated.30 
Table 1: Summary of the Literature of Differentially Expressed microRNA in 
Preeclampsia versus Control Placentas: qRT-PCR=quantitative reverse-
transcriptase polymerase chain reaction  
Citation Method Upregulated Downregulated 
Pineles et al. Am J 
Obstetric Gynecol 2007 
(31) 
qRT-PCR of placenta 210, 155, 181b, 182, 
200b, 154, 183 
N/A 
Hu et al. Clin Chem Lab 
Med 2009 (29) 
miR microarray and qRT-
PCR of severe PE placenta 
16, 29b, 195, 26b, 181a, 
335, 222 
N/A 
Zhu et al. Am J Obstet 
Gynecol 2009 (30) 
miR microarray and qRT-
PCR of severe PE placenta 
181a, 584, 30a-3p, 210, 
152, 517, 518b, 519e, 
638, 296, 362 
101, 10b, 218, 590, 204, 
32, 126,18a, 19a, 411, 377, 
154, 625, 144, 195, 150, 1, 
18b, 363, 342-3p, 450, 
223, 374 
Enquobahrie et al. Am J 
Obstet Gynecol 2010 (32) 
miR microarray and qRT-
PCR of placenta 
210 328, 584, 139-5p, 500, 
1247, 340-5p, 1 
Mayor-Lynn et al. Repro 
Sci 2010 (33) 
miR microarray and qRT-
PCR of placenta 
493 15b, 181a, 210, 483-5p 
Zhang et al. Am J Obstet 
Gynecol 2010 (34) 
qRT-PCR mechanism paper: 
miR-155 downregulates 
CYR61 gene involved in 
trophoblast function and 
angiogenic cells. 
N/A N/A 
 
 
It is important to note that, though there 
is ample evidence that miRNAs are 
dysregulated in preeclampsia, these 
studies were all carried out using RNA 
from placental tissues obtained after the 
patients had delivered. 
Methodologically, this clearly limits the 
use of miRNAs as a predictive tool. As 
obtaining placental tissue biopsies 
during gestation is neither feasible nor 
ethical, predictive miRNA assays must 
be done on RNA from a different source. 
Recently, Wu et al. showed that miRNA 
dysregulation can be detected in plasma 
drawn from women at 37 to 40 weeks 
gestation.35 Their study confirmed the 
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results of previous studies of placental 
tissues by detecting significant 
dysregulation of four miRNAs, miR-
130a, miR-144, miR-181a, and miR-
574-5p compared with plasma RNA 
from controls. They discovered a further 
eleven significantly dysregulated 
miRNAs not previously reported in other 
preeclampsia studies. This 
demonstrates that potentially meaningful 
miRNA expression changes can be 
detected in plasma samples. Having the 
ability to assay miRNA expression in a 
peripheral fluid opens the opportunity to 
carry out longitudinal cohort studies of 
preeclampsia using a minimally invasive 
sampling technique. 
First stimulated by an observation that 
very small microvesicular bodies shed 
by cultured human tumor cells into the 
media displayed molecular markers 
characteristic of the tumor plasma 
membranes themselves, Douglas Taylor 
and colleagues have shown that 
miRNAs, along with a specific range of 
mRNAs, that are shed by cancer cells 
into the blood stream are encapsulated 
within the structures called exosomes.36-
42 Importantly, these studies showed that 
the principle sources of RNA-containing 
exosomes are placenta and solid 
tumors.  Indeed, the most prolific 
exosome-producing tissue is the 
placenta.43,44 Several studies have 
shown that miRNAs in placental-derived 
exosomes can be reliably assayed in 
plasma and that they appear to 
participate in numerous crucial 
functions, including those related to 
immune suppression and 
angiogenesis.45 With respect to the 
reliability of these plasma-based miRNA 
assays, we recently determined 
expression of 377 human miRNAs in 
both placental tissue and plasma, albeit 
in a single individual. However, of the 
315 miRNAs expressed in placenta, we 
found that 286 (91%) were also 
detectable in plasma. Moreover, there 
was a highly significant correlation in 
expression levels of miRNAs (r = 0.6, p 
< .001, df = 284). 
Conclusion 
Preeclampsia is a serious and life-
threatening gestational condition whose 
etiology is still not well understood. In 
addition to its pathology, both the 
diagnosis and clinical management of 
preeclampsia are subjects of debate 
and controversy. One of the most 
important aspects impeding advances in 
understanding preeclampsia is that the 
majority of studies of the condition are 
carried out only after clinical signs such 
as progressive proteinuria and 
hypertension are clearly manifest. Thus, 
identification of a minimally invasive 
marker or markers that correlate with 
risk will be a major advance informing 
both clinical management and studies of 
pathogenesis. The discovery of 
miRNAs, gene expression regulators 
reliably detectable in both tissue and 
peripheral fluids, offers a potentially 
fertile field for identifying such markers. 
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